High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Merck & Co., Inc. (NYSE:MRK) reported second-quarter revenue of $16.6 billion, up 5% from a year earlier, driven by oncology, animal health and contributions from newer product launches. Revenue increased 4% excluding foreign exchange, according to Chief Financial Officer Caroline Litchfield. T
Moby summary of Merck & Co., Inc.'s Q2 2026 earnings call
Merck raises full-year guidance on robust KEYTRUDA and new product momentum, while navigating acquisition-related EPS impact and pipeline setbacks.
Merck (NYSE:MRK) shares moved higher in pre-market trading after the pharmaceutical company reported second-quarter 2026 results that exceeded Wall Street expectations and raised its full-year revenue guidance. Although Merck reduced its adjusted earnings outlook to reflect acquisition-related charges, investors welcomed the stronger-than-expected quarterly performance and improved sales forecast.
Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...
It is another big week on the earnings front with a lots of big name companies reporting. This week could make or break the market. This week we have SpaceX, Advanced Micro Devices, Palantir Technologies, Sandisk, Uber Technologies, McDonald’s, Caterpillar, Merck & Company, Disney, Shopify and Arista Networks all reporting in what shapes as a busy and pivotal week for stocks.
Global pharmaceutical company Merck (NYSE:MRK) will be announcing earnings results this Tuesday before market hours. Here’s what investors should know.
Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.
Shares of Merck & Co., Inc. (MRK) rise 3,453% since 1990 thanks to institutional investors.
Merck & Co. is expected to announce its second-quarter earnings in August, and Wall Street forecasts a double-digit decline in its profits.
Phibro trades near 10x forward earnings vs higher peer multiples as strong Q3 beat, margin gains and 2026 guidance support a modest upside case.
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
US stocks were expected to head in different directions on Thursday morning, as oil prices retreat but tech earnings overnight disappointed investors. Dow Jones futures were called 0.8% higher, but the S&P 500 was off 0.4% and Nasdaq futures were down 1.3%. The latter pair were...
Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai
Moby summary of Codexis, Inc.'s Q1 2026 earnings call
Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and reiterated full-year revenue guidance of $72 million
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
